Partnering

Reimagine cannabinoid-based medicine with us.

At Zelira we’re committed to world class science and clinical validation or our medicines and consumer products. We’re actively seeking partners to expand our global footprint and we welcome the opportunity to discuss a partnership.

Our focus is on helping people with specific conditions who feel that conventional treatments are providing limited or no relief. We’ve developed several pharmaceutical-grade cannabinoid-based medicines that are available to help improve the quality of life for these patients.

Zelira has a portfolio of proprietary revenue generating assets available now for licensing and distribution.

Our Prescription (Rx) medicines approach is to focus on specification indications. We design medicines to treat specific conditions and build supportive evidence through clinical trials. We are committed to taking these medicines to registration.

Our Consumer/OTC products are backed by world-class science to address areas of unmet need.

We also have a suite of pre-clinical assets showing substantial promise and potential.

Our portfolio of proprietary assets include:

Zelira has extensive experience in partnering with access to GMP manufacturing and distribution networks.

With the international market rapidly growing over the last decade and continuing to expand, patient demand for alternative solutions will only increase. Zelira is well positioned to respond to this growing world-wide market and are looking for key partners to accelerate this opportunity.